Cannabinol Use in Patients With Insomnia Disorder

Summary

This study aims to investigate the acute effects of cannabinol (CBN) 30 mg and 300 mg, versus placebo, on sleep architecture and next-day functioning in adults aged 25-65 years with chronic insomnia disorder.

Timeline

Start

2022-08-24

Primary completion

2023-08-29

Completion

2023-09-05

Outcome

Missed primary endpoint

paper Cannabinol did not significantly change WASO (300 mg: -6.3 min [95% CI: -18.2, +5.5], p = 0.29 PMID 41698831 ↗

Publications

• Lavender IG, Marshall NS, McCartney D, Cho G, Irwin C, Suraev A, Gordon R, Arnold JC, D'Rozario AL, Gordon CJ, Saini B, Sivam S, Zheng Y, Grunstein RR, Yee BJ, McGregor IS, Hoyos CM. Cannabinol for Acute Treatment of Insomnia Disorder in a Randomized Placebo-Controlled Crossover Trial. J Sleep Res. 2026 Feb 16:e70284. doi: 10.1111/jsr.70284. Online ahead of print.
• Lavender I, McCartney D, Marshall N, Suraev A, Irwin C, D'Rozario AL, Gordon CJ, Saini B, Grunstein RR, Yee B, McGregor I, Hoyos CM. Cannabinol (CBN; 30 and 300 mg) effects on sleep and next-day function in insomnia disorder ('CUPID' study): protocol for a randomised, double-blind, placebo-controlled, cross-over, three-arm, proof-of-concept trial. BMJ Open. 2023 Aug 23;13(8):e071148. doi: 10.1136/bmjopen-2022-071148.

Drugs

Indications